source
- Atea’s hepatitis C combo matches Gilead’s Epclusa in phase 3 trialBoston-based biotech Atea Pharmaceuticals reported that its once-daily hepatitis C combination of bemnifosbuvir and ruzasvir performed on par with Gilead's Epclusa in a pivotal phase 3 study. The…
- FDA warns investors that advisory panel reviews do not guarantee drug approval, cites concerns at Capricor and ReplimuneThe FDA issued a reminder to investors that the outcomes of advisory committee meetings are not final decisions on a drug’s fate. This week the agency released briefing documents highlighting conc…